David Williams

Dr. Williams began his career in academia at Appalachian State in 2003. As a former senior healthcare executive who has worked for both for-profit and not-for-profit organizations, he has experience working with health systems, managed care organizations, and physician practices. He continues to provide advice to former executive colleagues and students. He teaches at both the undergraduate and graduate levels. His research interests lie in factors associated with entrepreneurship and strategic management of healthcare organizations. His research has been presented at the Academy of Management, Association of University Programs in Health Administration, and Southern Management Association, among others. He has won both external research and internal service awards. The Pharmaceutical Research and Manufacturers of America has funded his research. He is a Fellow in the American College of Healthcare Executives. He was the undergraduate HCM Program Director for eight years, stepping down to become a Fulbright Scholar at the Management Center Innsbruck (Austria). When not at work, Dr. Williams enjoys the sporting life and arts with his family.

There are 14 included publications by David Williams :

TitleDateViewsBrief Description
Acquisitions In The Biopharmaceutical IPO Market: Collaboration, Competition And Co-opetition 2017 28 The present paper explores the little studied area concerning the acquisition of recent biopharmaceutical initial public offering firms. We examine the nature of the relationship between the acquiring firm and the acquired initial public offering fir...
The Costs Of Biopharmaceutical Firms Going Public In The U.S. 2015 2 The purpose of this paper is to examine the process and costs associated with biopharmaceutical firms undertaking an initial public offering. It discusses the direct and opportunity costs associated with this process. It shows the historical misprici...
An Empirical Study Of The Determinants Of Location Of Hospital Mergers And Acquisitions: 1997-2016 2018 10 The present paper examines characteristics related to the two parties involved with hospital mergers and acquisitions and how these affect the location of the merger or acquisition. Using a dataset provided by Levin Associates, we study announcements...
Human And Financial Capital As Determinants Of Biopharmaceutical IPO De-Listings 2012 12 The present study combines human capital theory with work on IPOs related to sources of financial capital of recent, publicly traded biopharmaceutical firms and relates this to the de-listing of these firms. The study follows the generally accepted v...
Human Capital And Agency Effects On CEO Compensation Of IPO Biopharmaceutical Firms And The Market's Response 2017 51 This paper examines the determinants of base pay and total incentive compensation packages of CEOs of biopharmaceutical firms that have recently gone public, and whether human capital and agency factors affect the market’s response to the initial pub...
The Inherent Risks Associated With Newly Traded Biopharmaceutical Firms 2018 32 Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses on creating drugs for humans. ...
Knowledge Transfers In The US Biopharmaceutical Market During A Time Of Transition 2019 61 The purpose of the paper is to examine the effects that firm factors, multinational corporations, and location have on explicit and tacit knowledge transfers originating in US biopharmaceutical firms during a time of transition. Examination of all kn...
Perspectives On Universal Health Insurance And Coverage Of Traditional Medicine: The Case Of Taiwan 2015 139 Inclusion of traditional medical therapies is one consideration in determining the range of services to be covered under universal health insurance. Having introduced a single-payer universal health insurance system in the 1990s that covers specified...
Post-Financial Crisis Transaction Trends Of U.S. Biotechnology Firms 2020 50 Transactions announcements can signal the health of an industry. This article examines all biotechnology transaction announcements occurring in the U.S. between 2010 and 2017. A baseline comparison to the prefinancial crisis transaction announcements...
Profiles Of Non-Traditional Adult MHA And MBA Students And Their Choice Of Degree Program 2012 3 The present study examines non-traditional, adult graduate students' demographic profile, and relates this to their enrollment in a master's degree program of study. We survey 407 students enrolled in either a master of business, healthcare, leadersh...
R&D Spending And Sources Of Funding Of Private US Biopharmaceutical Firms Seeking To Go Public 2010 15 This study analyzes the relationship between the amount of research and development (R&D) spending in private US biopharmaceutical firms before they go public and whether or not these firms tap into external sources of funding for investment before a...
The Role Of Pre-IPO Financial Indicators And Intermediaries In Aftermarket Performance And Survival In The US Biopharmaceutical Market 2012 4 This paper examines factors affecting the stock price, net proceeds, and subsequent survival of biopharmaceutical firms that have gone public between 1996 and 2007 in the USA. We find that the financial condition of biopharmaceutical firms going publ...
Strategic Groupings Of US Biotechnology Initial Public Offerings And A Measure Of Their Market Influence 2010 2 This study verifies the existence of strategic groups among biotechnology firms that have filed for an initial public offering (IPO). We found three distinct groupings based on the dimensions of competitive scope and growth. Differences also exist be...
Testing A Model Of Signals In The IPO Offer Process 2008 2 This study examines agency and market signals related to a sample of high-technology firms seeking an initial public offering (IPO). We test a model of the IPO offer process in high-technology firms. Results indicate that certain pre-market and prima...